Next Article in Journal
Mechanistic Insight into Royal Protein Inhibiting the Gram-Positive Bacteria
Next Article in Special Issue
Effect of Humanizing Mutations on the Stability of the Llama Single-Domain Variable Region
Previous Article in Journal
Deciphering the Importance of Glycosphingolipids on Cellular and Molecular Mechanisms Associated with Epithelial-to-Mesenchymal Transition in Cancer
Previous Article in Special Issue
Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell
Review

Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor

1
Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
2
Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium
3
In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
*
Author to whom correspondence should be addressed.
These authors share equal seniorship.
Biomolecules 2021, 11(1), 63; https://doi.org/10.3390/biom11010063
Received: 26 November 2020 / Revised: 30 December 2020 / Accepted: 1 January 2021 / Published: 6 January 2021
(This article belongs to the Special Issue The Therapeutic and Diagnostic Potential of Nanobodies)
Cell plasma membrane proteins are considered as gatekeepers of the cell and play a major role in regulating various processes. Transport proteins constitute a subclass of cell plasma membrane proteins enabling the exchange of molecules and ions between the extracellular environment and the cytosol. A plethora of human pathologies are associated with the altered expression or dysfunction of cell plasma membrane transport proteins, making them interesting therapeutic drug targets. However, the search for therapeutics is challenging, since many drug candidates targeting cell plasma membrane proteins fail in (pre)clinical testing due to inadequate selectivity, specificity, potency or stability. These latter characteristics are met by nanobodies, which potentially renders them eligible therapeutics targeting cell plasma membrane proteins. Therefore, a therapeutic nanobody-based strategy seems a valid approach to target and modulate the activity of cell plasma membrane transport proteins. This review paper focuses on methodologies to generate cell plasma membrane transport protein-targeting nanobodies, and the advantages and pitfalls while generating these small antibody-derivatives, and discusses several therapeutic nanobodies directed towards transmembrane proteins, including channels and pores, adenosine triphosphate-powered pumps and porters. View Full-Text
Keywords: nanobodies; cell plasma membrane transport proteins; drug target; therapy nanobodies; cell plasma membrane transport proteins; drug target; therapy
Show Figures

Figure 1

MDPI and ACS Style

Van Campenhout, R.; Muyldermans, S.; Vinken, M.; Devoogdt, N.; De Groof, T.W.M. Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor. Biomolecules 2021, 11, 63. https://doi.org/10.3390/biom11010063

AMA Style

Van Campenhout R, Muyldermans S, Vinken M, Devoogdt N, De Groof TWM. Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor. Biomolecules. 2021; 11(1):63. https://doi.org/10.3390/biom11010063

Chicago/Turabian Style

Van Campenhout, Raf, Serge Muyldermans, Mathieu Vinken, Nick Devoogdt, and Timo W.M. De Groof 2021. "Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor" Biomolecules 11, no. 1: 63. https://doi.org/10.3390/biom11010063

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop